A standardized clinical evaluation of patients affected by facioscapulohumeral muscular dystrophy: The FSHD clinical score

To define numerically the clinical severity of facioscapulohumeral muscular dystrophy (FSHD), we developed a protocol that quantifies muscle weakness by combining the functional evaluation of six muscle groups affected in this disease. To validate reproducibility of the protocol, 69 patients were recruited. Each patient was evaluated by at least five neurologists, and an FSHD severity score was given by each examiner. The degree of agreement among clinicians' evaluations was measured by kappa‐statistics. Nineteen subjects received a score between 0 and 1, 9 had a score between 2 and 4, 20 received a score between 5 and 10, and 8 had a score between 11 and 15. Of the 13 subjects with D4Z4 alleles within the normal range (ranging from 10 to 150 repeats), 12 obtained a score of 0 and only 1 had a score of 1. Kappa‐statistics showed a very high concordance for all muscle groups. We developed a simple, reliable, easily used tool to define the clinical expression of FSHD. Longitudinal studies will assess its sensitivity and utility in measuring changes for widespread use. Muscle Nerve, 2010

[1]  R. Griggs,et al.  Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy , 2001, Neurology.

[2]  M. Memmi,et al.  Identical de novo mutation at the D4F104S1 locus in monozygotic male twins affected by facioscapulohumeral muscular dystrophy (FSHD) with different clinical expression. , 1998, Journal of medical genetics.

[3]  M. Brooke,et al.  Clinical trial in duchenne dystrophy. I. The design of the protocol , 1981, Muscle & nerve.

[4]  M. Passos-Bueno,et al.  Asymptomatic carriers and gender differences in facioscapulohumeral muscular dystrophy (FSHD) , 2004, Neuromuscular Disorders.

[5]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[6]  R. Griggs,et al.  Evidence for anticipation and association of deletion size with severity in facioscapulohumerd muscular dystrophy , 1996 .

[7]  C. Angelini,et al.  Facioscapulohumeral Muscular Dystrophy and Occurrence of Heart Arrhythmia , 2006, European Neurology.

[8]  G. Bleijenberg,et al.  Effects of training and albuterol on pain and fatigue in facioscapulohumeral muscular dystrophy , 2007, Journal of Neurology.

[9]  F. Mangiola,et al.  Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype , 1999, Annals of neurology.

[10]  B. Everitt,et al.  Statistical methods for rates and proportions , 1973 .

[11]  O. Brouwer,et al.  The influence of handedness on the distribution of muscular weakness of the arm in facioscapulohumeral muscular dystrophy. , 1992, Brain : a journal of neurology.

[12]  C. Wijmenga,et al.  Genetic linkage map of facioscapulohumeral muscular dystrophy and five polymorphic loci on chromosome 4q35-qter. , 1992, American journal of human genetics.

[13]  P. Lunt,et al.  44th ENMC International Workshop: Facioscapulohumeral Muscular Dystrophy: Molecular Studies 19–21 July 1996, Naarden, The Netherlands , 1998, Neuromuscular Disorders.

[14]  J E Hewitt,et al.  FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. , 1993, Human molecular genetics.

[15]  P. Harper,et al.  Correlation between fragment size at D4F104S1 and age at onset or at wheelchair use, with a possible generational effect, accounts for much phenotypic variation in 4q35-facioscapulohumeral muscular dystrophy (FSHD) , 1995, Human molecular genetics.

[16]  S. Pandya,et al.  Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group. , 1994, Physical therapy.

[17]  W. Grove.  Statistical Methods for Rates and Proportions, 2nd ed , 1981 .